Key result
In a systematic review of 3,728 patients, angiotensin receptor blockers administered within 72 hours of acute stroke showed no effect on dependency, death, or vascular events at 1 to 6 months.
Why the study?
Do angiotensin receptor blockers (ARBs) administered in the acute phase of stroke reduce death and dependency?
Population
3,728 patients in the acute phase (≤72 hours) of stroke from 3 randomized controlled trials
Comparison
Angiotensin receptor blockers administered in… vs Placebo
Design
Systematic_review
Follow-up
up to 12 months
Authors
Loading...
ARBs should not be started within 72 h of acute stroke; confirms no outcome benefit and informs guideline updates.
Systematic Review (n=3,728)
Do angiotensin receptor blockers (ARBs) administered in the acute phase of stroke reduce death and dependency?
This systematic review found no evidence that administering ARBs in the acute phase of stroke improves short- or medium-term outcomes such as death or dependency.
Lattanzi et al. (2013) conducted a systematic review in Acute stroke (n=3,728). Angiotensin receptor blockers (ARBs) vs. Placebo was evaluated on Death and dependency. In a systematic review of 3,728 patients, angiotensin receptor blockers administered within 72 hours of acute stroke showed no effect on dependency, death, or vascular events at 1 to 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: